Bard S1294108D4 PowerPICC Provena Catheter w/ SOLO Valve Technology and Sherlock 3CG Tip Positioning System (TPS) Stylet 4F 1/EA

• Model: S1294108D4
• Catheter Type: Peripherally Inserted Central Catheter (PICC)
• French Size: 4 Fr
• Lumen Configuration: Dual lumen
• Valve Technology: SOLO™ integrated valve
• Tip Positioning: Sherlock 3CG Tip Positioning System (TPS) Stylet

The Bard PowerPICC Provena™ Catheter with SOLO™ Valve Technology and Sherlock 3CG Tip Positioning System (TPS) Stylet delivers advanced central venous access with reduced maintenance and enhanced clinical safety. Engineered for both short- and long-term intravenous therapy, this 4 Fr dual-lumen PICC supports a wide range of treatments—including fluid infusion, blood draws, central venous pressure monitoring, and power injection of contrast media—making it a versatile choice for hospitals and high-acuity settings. With SOLO™ Valve Technology built-in, clinicians can eliminate the need for heparin flushes, streamlining care protocols and reducing complications associated with heparin use.

What sets this catheter apart is the inclusion of the Sherlock 3CG Tip Positioning System (TPS) Stylet, which enables real-time, bedside confirmation of the catheter tip’s location during insertion. This innovative system reduces reliance on routine x-rays, accelerating placement workflows and enhancing patient safety while adhering to best practices for PICC positioning. The combination of SOLO™ Valve and Sherlock 3CG technologies supports clinicians in achieving reliable performance and precision with every insertion.

Designed for durability and comfort, the PowerPICC Provena™ catheter’s smaller profile helps align with vascular access guidelines that prioritize catheter-to-vein ratio optimization, potentially reducing vessel trauma and promoting long-term patency. Whether deployed in critical care, oncology, or infusion therapy departments, this advanced PICC solution improves workflow efficiencies, supports a wide array of infusion needs, and enhances overall patient outcomes.